Profil bibliographique

James W. Evans

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

18Publications signalées
0Citations signalées
0Affiliations récentes

Les domaines associés

Cancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysProtein Degradation and InhibitorsHER2/EGFR in Cancer ResearchFerroptosis and cancer prognosis

Les publications récentes

Accès ouvert 2026 other OpenAlex

Figure 6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) doublet maximizes pathway suppression and favorably modulates the TME of the ICB-refractory 3LL-ΔNRAS model. A, PD of elironrasib, daraxonrasib, and the RAS(ON) doublet in subcutaneous tumors shown as the relative change in pERK expression in tumor cells. Tumor-bearing mice were treated …

0 citations
Accès ouvert 2026 other OpenAlex

Figure 5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Elironrasib and daraxonrasib drive immune-dependent CRs, favorably modulate the TME, and synergize with anti–PD-1 in the immunogenic KPAR1.3 model. A, Tumor growth of subcutaneous tumors treated for 32 days (dashed line indicated treatment stop) with vehicle, elironrasib at 100 mg/kg, daraxonrasib at …

0 citations
Accès ouvert 2026 other OpenAlex

Data from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Abstract To address RAS pathway hyperactivation and targeted therapy resistance in KRASG12C-mutant non–small cell lung cancer (NSCLC), we evaluated the potential of the RAS(ON) G12C-selective covalent inhibitor elironrasib and the RAS(ON) multi-selective inhibitor daraxonrasib combination to maximize RAS pathway suppression and forestall …

0 citations
Accès ouvert 2026 other OpenAlex

Figure 3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) inhibitor doublet drives sustained RAS signaling suppression, inhibits cell proliferation, and induces apoptosis in vivo. A, Target engagement of KRASG12C protein by elironrasib in NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft tumors, shown as the percentage of cross-linked KRASG12C by elironrasib relative to …

0 citations
Accès ouvert 2026 other OpenAlex

Figure 2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

RAS(ON) inhibitor doublet forestalls resistance driven by elevated RAS pathway flux. A, Antitumor activity of elironrasib and daraxonrasib as single agents or in combination in the NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft model (n = 8–15 per group). Tumor-bearing mice were treated with …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

Supplementary Figure 1. The RAS(ON) inhibitor doublet induces deep and durable responses in KRASG12C-mutant NSCLC models and is tolerated based on animal body weight assessment. Supplementary Figure 2. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vitro. Supplementary Figure 3. The RAS(ON) …

0 citations
Accès ouvert 2026 other OpenAlex

Figure 4 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

Wei Xing, Cristina Blaj, M. Ali Al-Radhawi, Lo Lai et autres

PK/TE/PD modeling of complementary mechanisms predicts the superiority of the RAS(ON) inhibitor doublet over monotherapies in the context of KRASG12C overexpression. A, The model captures the blood PK of daraxonrasib at 25 mg/kg and plasma PK of elironrasib at 100 mg/kg upon …

0 citations
Profil ORCIDNotice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.